Reprieve Cardiovascular is a health care startup that aims to revolutionize the treatment of heart failure, potentially benefiting over 25 million patients worldwide. The company is focused on developing innovative therapies to bring intelligence to decongestion management, with the goal of safely accelerating fluid removal for heart failure patients. In 2018, Reprieve Cardiovascular was founded and is currently headquartered in Milford, Massachusetts, United States. The company recently secured a significant $42.00M Series A investment on 20 February 2024 from prominent investors including Arboretum Ventures, Lightstone Ventures, Santé Ventures, Deerfield Management, and GenesisCapital. In 2022, Reprieve initiated the FASTR Trial (pilot study) aiming to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy for patients with acute decompensated heart failure. With its innovative approach and strategic partnerships, Reprieve Cardiovascular is well-positioned to make a significant impact in the field of cardiovascular health and medical device innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $42.00M | 5 |
|
20 Feb 2024 |
| Venture Round | $12.05M | - | 17 Nov 2023 | |
| Venture Round | $15.00M | - | 07 Jun 2022 | |
| Series A | $15.00M | 1 | Deerfield | 04 Aug 2020 |
| Venture Round | $7.00M | 1 | Abiomed | 12 Sep 2018 |
No recent news or press coverage available for Reprieve Cardiovascular.
We care about your data, and we'd love to use cookies make your experience better.
